title: Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care.
abstract: OBJECTIVE
  To determine whether, in the treatment of major depression in primary care, a brief psychological treatment (problem solving) was (a) as effective as antidepressant drugs and more effective than placebo; (b) feasible in practice; and (c) acceptable to patients.
  
  
  METHODS
  Randomised controlled trial of problem solving treatment, amitriptyline plus standard clinical management, and drug placebo plus standard clinical management. Each treatment was delivered in six sessions over 12 weeks.
  
  
  METHODS
  Primary care in Oxfordshire.
  
  
  METHODS
  91 patients in primary care who had major depression.
  
  
  METHODS
  Observer and self reported measures of severity of depression, self reported measure of social outcome, and observer measure of psychological symptoms at six and 12 weeks; self reported measure of patient satisfaction at 12 weeks. Numbers of patients recovered at six and 12 weeks.
  
  
  RESULTS
  At six and 12 weeks the difference in score on the Hamilton rating scale for depression between problem solving and placebo treatments was significant (5.3 (95% confidence interval 1.6 to 9.0) and 4.7 (0.4 to 9.0) respectively), but the difference between problem solving and amitriptyline was not significant (1.8 (-1.8 to 5.5) and 0.9 (-3.3 to 5.2) respectively). At 12 weeks 60% (18/30) of patients given problem solving treatment had recovered on the Hamilton scale compared with 52% (16/31) given amitriptyline and 27% (8/30) given placebo. Patients were satisfied with problem solving treatment; all patients who completed treatment (28/30) rated the treatment as helpful or very helpful. The six sessions of problem solving treatment totalled a mean therapy time of 3 1/2 hours.
  
  
  CONCLUSIONS
  As a treatment for major depression in primary care, problem solving treatment is effective, feasible, and acceptable to patients.
authors.affiliation: Department of Psychiatry, University of Oxford, Warneford Hospital.
authors.forename: L M
authors.initials: LM
authors.lastname: Mynors-Wallis
authors.forename: D H
authors.initials: DH
authors.lastname: Gath
authors.forename: A R
authors.initials: AR
authors.lastname: Lloyd-Thomas
authors.forename: D
authors.initials: D
authors.lastname: Tomlinson
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000639:Amitriptyline / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010352:Patient Dropouts; D017060:Patient Satisfaction; D018579:Patient Selection; D011320:Primary Health Care; D011340:Problem Solving; D011569:Psychiatric Status Rating Scales; D016896:Treatment Outcome
chemical_list: D000639:Amitriptyline